Skip to main content

Adverum Biotechnologies Value Stock - Dividend - Research Selection

Adverum biotechnologies

ISIN: US00773U1088 , WKN: A2AJW8

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-05-02
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees enterin

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

2025-04-22
NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. . Such investors are advised to contact Danielle Peyton at...

Adverum Biotechnologies: Q4 Earnings Snapshot

2025-04-15
REDWOOD CITY, Calif. AP) — Adverum Biotechnologies Inc. ADVM) on Tuesday reported a loss of $40.9 million in its fourth quarter.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

2025-04-15
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

2025-04-15
LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum...

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-04-04
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award as an inducement material to the new employee's employment in accordance

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

2025-03-31
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the Investors sec

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

2025-03-03
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLO

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

2025-02-25
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A r

3 US Penny Stocks With Market Caps Below $400M

2025-02-18
As major U.S. stock indexes hover near record highs, investors are closely watching market movements and economic indicators for signs of future trends. For those interested in exploring smaller or newer companies, penny stocks—though an outdated term—remain a viable investment area with potential value. These stocks, often characterized by lower price points and the possibility of growth, can be particularly appealing when backed by strong financials and solid fundamentals. In this article,...